NR548 EXAMS 1-4 WEEKS 1-8 COVERED ACTUAL 2026/2027 -
COMPLETE QUESTIONS WITH DETAILED RATIONALES 100%
VERIFIED ANSWERS - PASS GUARANTEED - A+ GRADED
190 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Demonstrate mastery of core concepts
2 NR548 Exams 1
3 4 Weeks 1
4 8 Covered Actual 2026
5 2027
6 Complete Questions with Detailed Rationales 100% Verified Answers
7 Pass Guaranteed
8 A+ Graded
9 Foundations of NR548 Exams 1-4 Weeks 1-8 Covered Actual 2026/2027 - Complete Questions with
Detailed Rationales 100% Verified Answers - Pass Guaranteed - A+ Graded
10 Applied NR548 Exams 1-4 Weeks 1-8 Covered Actual 2026/2027 - Complete Questions with Detailed
Rationales 100% Verified Answers - Pass Guaranteed - A+ Graded
11 Advanced NR548 Exams 1-4 Weeks 1-8 Covered Actual 2026/2027 - Complete Questions with Detailed
Rationales 100% Verified Answers - Pass Guaranteed - A+ Graded
12 NR548 Exams 1-4 Weeks 1-8 Covered Actual 2026/2027 - Complete Questions with Detailed Rationales
100% Verified Answers - Pass Guaranteed - A+ Graded Review
Page 1
,Q1 DEMONSTRATE MASTERY OF CORE CONCEPTS
In a patient with treatment-resistant depression who has failed two adequate trials
of SSRIs, which augmentation strategy is most supported by current evidence for
rapid onset and sustained efficacy?
A. Adding aripiprazole at a starting dose of 2 mg/day CORRECT
B. Adding lithium carbonate titrated to a serum level of 0.6-0.8 mEq/L
C. Augmenting with low-dose quetiapine (50-100 mg at bedtime)
D. Switching to a monoamine oxidase inhibitor (MAOI) after a 14-day washout
RATIONALE: Aripiprazole is FDA-approved for adjunctive treatment of major depressive disorder
and has shown rapid onset and sustained efficacy in multiple trials. Lithium augmentation has
evidence but requires monitoring and has a slower onset. Quetiapine is also approved but has a
less favorable metabolic profile. Switching to an MAOI is a strategy but not considered first-line
augmentation and carries dietary restrictions.
Q2 DEMONSTRATE MASTERY OF CORE CONCEPTS
A patient on vancomycin for MRSA pneumonia develops acute kidney injury (AKI)
with a rising serum creatinine. The patient's vancomycin trough is 25 mg/L. Which
intervention is most appropriate based on current guidelines?
A. Continue current dose and recheck trough in 48 hours
B. Hold the next dose and re-dose based on AUC-guided monitoring CORRECT
C. Switch to linezolid immediately
D. Reduce the dose by 50% and continue trough monitoring
RATIONALE: Current guidelines recommend AUC-guided vancomycin monitoring (target
AUC/MIC 400-600) to minimize AKI. A trough of 25 mg/L with AKI suggests overexposure;
holding a dose and re-dosing based on AUC is appropriate. Continuing the same dose risks
further injury. Switching to linezolid is not automatically indicated unless vancomycin is failing or
contraindicated. Dose reduction without holding may still lead to accumulation.
Page 2
,Q3 DEMONSTRATE MASTERY OF CORE CONCEPTS
Which of the following best describes the primary mechanism of action of
glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the management of type
2 diabetes?
A. Direct stimulation of pancreatic beta cells to increase insulin secretion independent of glucose
B. Inhibition of renal glucose reabsorption via SGLT2
C. Glucose-dependent enhancement of insulin secretion and suppression of glucagon release
CORRECT
D. Activation of PPAR-gamma nuclear receptors to improve insulin sensitivity
RATIONALE: GLP-1 RAs mimic incretin hormones, enhancing glucose-dependent insulin
secretion, suppressing glucagon, and slowing gastric emptying. They do not stimulate insulin
independent of glucose (unlike sulfonylureas). SGLT2 inhibition is the mechanism of
canagliflozin. PPAR-gamma activation is the mechanism of thiazolidinediones.
Q4 DEMONSTRATE MASTERY OF CORE CONCEPTS
A patient with atrial fibrillation (AF) and a CHA2DS2-VASc score of 3 is started on
apixaban. Which laboratory parameter is most important to monitor during
therapy?
A. Activated partial thromboplastin time (aPTT)
B. International normalized ratio (INR)
C. Serum creatinine and complete blood count CORRECT
D. Anti-factor Xa levels
RATIONALE: Apixaban is a direct oral anticoagulant (DOAC) that does not require routine
coagulation monitoring; however, renal function (serum creatinine) should be assessed
periodically to adjust dosing, and CBC for bleeding. aPTT and INR are not reliable for apixaban.
Anti-factor Xa is not routinely recommended. Monitoring renal function and blood counts is
essential for safety.
Page 3
, Q5 DEMONSTRATE MASTERY OF CORE CONCEPTS
Which of the following best describes the rationale for using a combination of a
long-acting beta-agonist (LABA) and an inhaled corticosteroid (ICS) in moderate
persistent asthma?
A. LABA provides rapid relief of acute bronchospasm while ICS reduces airway inflammation
B. ICS suppresses inflammation while LABA provides prolonged bronchodilation, and the
combination improves adherence CORRECT
C. LABA increases the anti-inflammatory effect of ICS by upregulating corticosteroid receptors
D. The combination reduces the risk of asthma exacerbations by blocking both leukotriene and
histamine pathways
RATIONALE: ICS reduce airway inflammation while LABAs provide prolonged bronchodilation;
combining them improves symptom control and reduces exacerbations compared to higher-dose
ICS alone. LABAs are not for acute relief (that is SABA). The combination does not directly
upregulate corticosteroid receptors, and it does not block leukotrienes/histamine as primary
mechanism.
Q6 DEMONSTRATE MASTERY OF CORE CONCEPTS
A patient with heart failure with reduced ejection fraction (HFrEF) is on lisinopril,
carvedilol, and furosemide. Which additional medication has been shown to
reduce mortality and is now recommended as part of the foundational therapy?
A. Spironolactone CORRECT
B. Digoxin
C. Hydralazine and isosorbide dinitrate
D. Ivabradine
RATIONALE: In HFrEF, mineralocorticoid receptor antagonists (MRAs) like spironolactone reduce
mortality and are part of the four pillars of guideline-directed medical therapy (along with
ARNI/ACEi, beta-blocker, and SGLT2i). Digoxin improves symptoms but not mortality.
Hydralazine/nitrates are for African American patients or those intolerant to ACEi/ARB.
Ivabradine is used for heart rate control in select patients after beta-blocker optimization.
Page 4
COMPLETE QUESTIONS WITH DETAILED RATIONALES 100%
VERIFIED ANSWERS - PASS GUARANTEED - A+ GRADED
190 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Demonstrate mastery of core concepts
2 NR548 Exams 1
3 4 Weeks 1
4 8 Covered Actual 2026
5 2027
6 Complete Questions with Detailed Rationales 100% Verified Answers
7 Pass Guaranteed
8 A+ Graded
9 Foundations of NR548 Exams 1-4 Weeks 1-8 Covered Actual 2026/2027 - Complete Questions with
Detailed Rationales 100% Verified Answers - Pass Guaranteed - A+ Graded
10 Applied NR548 Exams 1-4 Weeks 1-8 Covered Actual 2026/2027 - Complete Questions with Detailed
Rationales 100% Verified Answers - Pass Guaranteed - A+ Graded
11 Advanced NR548 Exams 1-4 Weeks 1-8 Covered Actual 2026/2027 - Complete Questions with Detailed
Rationales 100% Verified Answers - Pass Guaranteed - A+ Graded
12 NR548 Exams 1-4 Weeks 1-8 Covered Actual 2026/2027 - Complete Questions with Detailed Rationales
100% Verified Answers - Pass Guaranteed - A+ Graded Review
Page 1
,Q1 DEMONSTRATE MASTERY OF CORE CONCEPTS
In a patient with treatment-resistant depression who has failed two adequate trials
of SSRIs, which augmentation strategy is most supported by current evidence for
rapid onset and sustained efficacy?
A. Adding aripiprazole at a starting dose of 2 mg/day CORRECT
B. Adding lithium carbonate titrated to a serum level of 0.6-0.8 mEq/L
C. Augmenting with low-dose quetiapine (50-100 mg at bedtime)
D. Switching to a monoamine oxidase inhibitor (MAOI) after a 14-day washout
RATIONALE: Aripiprazole is FDA-approved for adjunctive treatment of major depressive disorder
and has shown rapid onset and sustained efficacy in multiple trials. Lithium augmentation has
evidence but requires monitoring and has a slower onset. Quetiapine is also approved but has a
less favorable metabolic profile. Switching to an MAOI is a strategy but not considered first-line
augmentation and carries dietary restrictions.
Q2 DEMONSTRATE MASTERY OF CORE CONCEPTS
A patient on vancomycin for MRSA pneumonia develops acute kidney injury (AKI)
with a rising serum creatinine. The patient's vancomycin trough is 25 mg/L. Which
intervention is most appropriate based on current guidelines?
A. Continue current dose and recheck trough in 48 hours
B. Hold the next dose and re-dose based on AUC-guided monitoring CORRECT
C. Switch to linezolid immediately
D. Reduce the dose by 50% and continue trough monitoring
RATIONALE: Current guidelines recommend AUC-guided vancomycin monitoring (target
AUC/MIC 400-600) to minimize AKI. A trough of 25 mg/L with AKI suggests overexposure;
holding a dose and re-dosing based on AUC is appropriate. Continuing the same dose risks
further injury. Switching to linezolid is not automatically indicated unless vancomycin is failing or
contraindicated. Dose reduction without holding may still lead to accumulation.
Page 2
,Q3 DEMONSTRATE MASTERY OF CORE CONCEPTS
Which of the following best describes the primary mechanism of action of
glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the management of type
2 diabetes?
A. Direct stimulation of pancreatic beta cells to increase insulin secretion independent of glucose
B. Inhibition of renal glucose reabsorption via SGLT2
C. Glucose-dependent enhancement of insulin secretion and suppression of glucagon release
CORRECT
D. Activation of PPAR-gamma nuclear receptors to improve insulin sensitivity
RATIONALE: GLP-1 RAs mimic incretin hormones, enhancing glucose-dependent insulin
secretion, suppressing glucagon, and slowing gastric emptying. They do not stimulate insulin
independent of glucose (unlike sulfonylureas). SGLT2 inhibition is the mechanism of
canagliflozin. PPAR-gamma activation is the mechanism of thiazolidinediones.
Q4 DEMONSTRATE MASTERY OF CORE CONCEPTS
A patient with atrial fibrillation (AF) and a CHA2DS2-VASc score of 3 is started on
apixaban. Which laboratory parameter is most important to monitor during
therapy?
A. Activated partial thromboplastin time (aPTT)
B. International normalized ratio (INR)
C. Serum creatinine and complete blood count CORRECT
D. Anti-factor Xa levels
RATIONALE: Apixaban is a direct oral anticoagulant (DOAC) that does not require routine
coagulation monitoring; however, renal function (serum creatinine) should be assessed
periodically to adjust dosing, and CBC for bleeding. aPTT and INR are not reliable for apixaban.
Anti-factor Xa is not routinely recommended. Monitoring renal function and blood counts is
essential for safety.
Page 3
, Q5 DEMONSTRATE MASTERY OF CORE CONCEPTS
Which of the following best describes the rationale for using a combination of a
long-acting beta-agonist (LABA) and an inhaled corticosteroid (ICS) in moderate
persistent asthma?
A. LABA provides rapid relief of acute bronchospasm while ICS reduces airway inflammation
B. ICS suppresses inflammation while LABA provides prolonged bronchodilation, and the
combination improves adherence CORRECT
C. LABA increases the anti-inflammatory effect of ICS by upregulating corticosteroid receptors
D. The combination reduces the risk of asthma exacerbations by blocking both leukotriene and
histamine pathways
RATIONALE: ICS reduce airway inflammation while LABAs provide prolonged bronchodilation;
combining them improves symptom control and reduces exacerbations compared to higher-dose
ICS alone. LABAs are not for acute relief (that is SABA). The combination does not directly
upregulate corticosteroid receptors, and it does not block leukotrienes/histamine as primary
mechanism.
Q6 DEMONSTRATE MASTERY OF CORE CONCEPTS
A patient with heart failure with reduced ejection fraction (HFrEF) is on lisinopril,
carvedilol, and furosemide. Which additional medication has been shown to
reduce mortality and is now recommended as part of the foundational therapy?
A. Spironolactone CORRECT
B. Digoxin
C. Hydralazine and isosorbide dinitrate
D. Ivabradine
RATIONALE: In HFrEF, mineralocorticoid receptor antagonists (MRAs) like spironolactone reduce
mortality and are part of the four pillars of guideline-directed medical therapy (along with
ARNI/ACEi, beta-blocker, and SGLT2i). Digoxin improves symptoms but not mortality.
Hydralazine/nitrates are for African American patients or those intolerant to ACEi/ARB.
Ivabradine is used for heart rate control in select patients after beta-blocker optimization.
Page 4
